Date:2nd May 2021

Your Name: Cora Waldstein

Manuscript Title: Melanoma brain metastases: The outcome of whole brain radiation therapy in the era of effective

systemic therapy

Manuscript number (if known): TRO-21-6

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, | None | |
| | provision of study materials, | | |
| | medical writing, article processing charges, etc.) | | |
| | No time limit for this item. | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | None | |
| | any entity (if not indicated in item #1 above). | | |
| 3 | Royalties or licenses | None | |
| | , | | |
| | | | |
| 4 | Consulting fees | None | |
| | | | |

| 6 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony | None | | | | |
|-----|---|------|--|--|--|--|
| 7 | Support for attending meetings and/or travel | None | | | | |
| 8 | Patents planned, issued or pending | None | | | | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | None | | | | |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None | | | | |
| 11 | Stock or stock options | None | | | | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | None | | | | |
| 13 | Other financial or non- financial interests | None | | | | |
| Ple | Please summarize the above conflict of interest in the following box: | | | | | |

| No potential conflict of interest | | |
|-----------------------------------|--|--|
| | | |
| | | |
| | | |

Date:18th April 2021 Your Name: Wei Wang

Manuscript Title: Melanoma brain metastases: The outcome of whole brain radiation therapy in the era of effective

systemic therapy

Manuscript number (if known): TRO-21-6

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None None | pranning of the work |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | None | |
| 3 | Royalties or licenses | None | |
| 4 | Consulting fees | None | |

| 6 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony | None | | | | |
|-----|---|------|--|--|--|--|
| 7 | Support for attending meetings and/or travel | None | | | | |
| 8 | Patents planned, issued or pending | None | | | | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | None | | | | |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None | | | | |
| 11 | Stock or stock options | None | | | | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | None | | | | |
| 13 | Other financial or non- financial interests | None | | | | |
| Ple | Please summarize the above conflict of interest in the following box: | | | | | |

| No potential conflict of interest | | |
|-----------------------------------|--|--|
| | | |
| | | |
| | | |

Date:18th April 2021 Your Name: Serigne Lo

Manuscript Title: Melanoma brain metastases: The outcome of whole brain radiation therapy in the era of effective

systemic therapy

Manuscript number (if known): TRO-21-6

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None None | pranning of the work |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | None | |
| 3 | Royalties or licenses | None | |
| 4 | Consulting fees | None | |

| 6 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony | None | | | | |
|-----|---|------|--|--|--|--|
| 7 | Support for attending meetings and/or travel | None | | | | |
| 8 | Patents planned, issued or pending | None | | | | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | None | | | | |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None | | | | |
| 11 | Stock or stock options | None | | | | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | None | | | | |
| 13 | Other financial or non- financial interests | None | | | | |
| Ple | Please summarize the above conflict of interest in the following box: | | | | | |

| No potential conflict of interest | | |
|-----------------------------------|--|--|
| | | |
| | | |
| | | |

Date:18th April 2021

Your Name: Brindha Shivalingham

Manuscript Title: Melanoma brain metastases: The outcome of whole brain radiation therapy in the era of effective

systemic therapy

Manuscript number (if known): TRO-21-6

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None None | pranning of the work |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | None | |
| 3 | Royalties or licenses | None | |
| 4 | Consulting fees | None | |

| 6 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony | None | | | | |
|-----|---|------|--|--|--|--|
| 7 | Support for attending meetings and/or travel | None | | | | |
| 8 | Patents planned, issued or pending | None | | | | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | None | | | | |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None | | | | |
| 11 | Stock or stock options | None | | | | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | None | | | | |
| 13 | Other financial or non- financial interests | None | | | | |
| Ple | Please summarize the above conflict of interest in the following box: | | | | | |

| No potential conflict of interest | | |
|-----------------------------------|--|--|
| | | |
| | | |
| | | |

Date:18th April 2021

Your Name: Gerald Fogarty

Manuscript Title: Melanoma brain metastases: The outcome of whole brain radiation therapy in the era of effective

systemic therapy

Manuscript number (if known): TRO-21-6

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None None | pranning of the work |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | None | |
| 3 | Royalties or licenses | None | |
| 4 | Consulting fees | None | |

| 6 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony | None | | | |
|-----|---|------|--|--|--|
| 7 | Support for attending meetings and/or travel | None | | | |
| 8 | Patents planned, issued or pending | None | | | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | None | | | |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None | | | |
| 11 | Stock or stock options | None | | | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | None | | | |
| 13 | Other financial or non- financial interests | None | | | |
| Ple | Please summarize the above conflict of interest in the following box: | | | | |

| No potential conflict of interest | | |
|-----------------------------------|--|--|
| | | |
| | | |
| | | |

Date:18th April 2021

Your Name: Matteo Carlino

Manuscript Title: Melanoma brain metastases: The outcome of whole brain radiation therapy in the era of effective

systemic therapy

Manuscript number (if known): TRO-21-6

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None None | planning of the work |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | None | |
| 3 | Royalties or licenses | None | |
| 4 | Consulting fees | None | |

| 5 | Payment or honoraria for | None | |
|----|----------------------------------|------------------------|--|
| | lectures, presentations, | | |
| | speakers bureaus, | | |
| | manuscript writing or | | |
| | educational events | | |
| 6 | Payment for expert | None | |
| | testimony | | |
| 7 | Support for attending | Travel support and | |
| ′ | meetings and/or travel | registration fees from | |
| | meetings and/or traver | Bristol Myers Squibb & | |
| | | MSD | |
| 8 | Patents planned, issued or | None | |
| | pending | | |
| | | | |
| 9 | Participation on a Data | Consultancy | |
| | Safety Monitoring Board or | fees/honorarium: Board | |
| | Advisory Board | member Bristol Myers | |
| | | Squibb, MSD, Novartis | |
| 10 | Leadership or fiduciary role | None | |
| | in other board, society, | | |
| | committee or advocacy | | |
| | group, paid or unpaid | | |
| 11 | Stock or stock options | None | |
| | | | |
| | | | |
| 12 | Receipt of equipment, | None | |
| | materials, drugs, medical | | |
| | writing, gifts or other services | | |
| 13 | Other financial or non- | None | |
| 15 | financial interests | | |
| | | | |
| | | | |

Please summarize the above conflict of interest in the following box:

| Matteo | Carlino | received | Travel | support | and | registration | fees | from | Bristol | Myers | Squibb | & | MSD | and |
|---------|--|----------|--------|---------|-----|--------------|------|------|---------|-------|--------|---|-----|-----|
| honorar | honorarium from Bristol Myers Squibb, MSD, Novartis. | | | | | | | | | | | | | |

Please place an "X" next to the following statement to indicate your agreement:

Date:18th April 2021

Your Name: Alexander Menzies

Manuscript Title: Melanoma brain metastases: The outcome of whole brain radiation therapy in the era of effective

systemic therapy

Manuscript number (if known): TRO-21-6

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | Salary support from Cancer Institute NSW fellowship and Melanoma Institute Australia | |
| 3 | Royalties or licenses | None | |
| 4 | Consulting fees | None | |

| - | | <u></u> | | | |
|----|---|--------------------------|--|--|--|
| | | | | | |
| | | | | | |
| 5 | Payment or honoraria for | None | | | |
| | lectures, presentations, | | | | |
| | speakers bureaus, | | | | |
| | manuscript writing or | | | | |
| | educational events | | | | |
| 6 | Payment for expert | None | | | |
| | testimony | | | | |
| | | | | | |
| 7 | Support for attending | Bristol Myers Squibb | | | |
| | meetings and/or travel | | | | |
| 8 | Patents planned, issued or | None | | | |
| | pending | | | | |
| 9 | Participation on a Data | Consultancy | | | |
| | Safety Monitoring Board or | fees/honorarium: Bristol | | | |
| | Advisory Board | Myers Squibb, MSD, | | | |
| | | Novartis, Roche, Pierre | | | |
| | | Fabre, | | | |
| 10 | Leadership or fiduciary role | None | | | |
| | in other board, society, | | | | |
| | committee or advocacy | | | | |
| | group, paid or unpaid | | | | |
| 11 | Stock or stock options | None | | | |
| | | | | | |
| | | | | | |
| 12 | Receipt of equipment, | None | | | |
| | materials, drugs, medical | | | | |
| | writing, gifts or other | | | | |
| | services | | | | |
| 13 | Other financial or non- | None | | | |
| | financial interests | | | | |
| | Please summarize the above conflict of interest in the following box: | | | | |

Alexander Menzies received Salary support from Cancer Institute NSW fellowship and Melanoma Institute Australia, travel support from Bristol Myers Squibb and consultancy fee from Bristol Myers Squibb, MSD, Novartis, Roche, Pierre Fabre.

Please place an "X" next to the following statement to indicate your agreement:

Date:18th April 2021

Your Name: Georgina V Long

Manuscript Title: Melanoma brain metastases: The outcome of whole brain radiation therapy in the era of effective

systemic therapy

Manuscript number (if known): TRO-21-6

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | Salary support from NHMRC fellowship and the University of Sydney Medical Foundation | |
| | | | |
| 3 | Royalties or licenses | None | |
| 4 | Consulting fees | None | |

| 5 | Payment or honoraria for | None | |
|----|------------------------------|--|--|
| | lectures, presentations, | | |
| | speakers bureaus, | | |
| | manuscript writing or | | |
| _ | educational events | | |
| 6 | Payment for expert | None | |
| | testimony | | |
| _ | | | |
| 7 | Support for attending | Support for travel or | |
| | meetings and/or travel | accommodation Bristol Myers Squibb, Novartis, | |
| | | Roche, Amgen, Pierre | |
| | | Fabre, MERCK and Array | |
| 8 | Patents planned, issued or | None | |
| | pending | | |
| | . 5 | | |
| 9 | Participation on a Data | Consultancy fees/ | |
| | Safety Monitoring Board or | honorarium Bristol | |
| | Advisory Board | Myers Squibb, Novartis, | |
| | | Roche, Amgen, Pierre | |
| | | Fabre, MERCK and Array | |
| 10 | Leadership or fiduciary role | None | |
| | in other board, society, | | |
| | committee or advocacy | | |
| 11 | group, paid or unpaid | Nana | |
| 11 | Stock or stock options | None | |
| | | | |
| 12 | Receipt of equipment, | None | |
| 12 | materials, drugs, medical | None | |
| | writing, gifts or other | | |
| | services | | |
| 13 | Other financial or non- | None | |
| | financial interests | | |
| | | | |

Please summarize the above conflict of interest in the following box:

Georgina Long received Salary support from NHMRC fellowship and the University of Sydney Medical Foundation, travel support from Bristol Myers Squibb, Novartis, Roche, Amgen, Pierre Fabre, MERCK and Array. She also received Consultancy fees from Bristol Myers Squibb, Novartis, Roche, Amgen, Pierre Fabre, MERCK and Array.

Please place an "X" next to the following statement to indicate your agreement:

Date:18th April 2021

Your Name: Angela Hong

Manuscript Title: Melanoma brain metastases: The outcome of whole brain radiation therapy in the era of effective

systemic therapy

Manuscript number (if known): TRO-21-6

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, | None | |
| | provision of study materials, medical writing, article | | |
| | processing charges, etc.) | | |
| | No time limit for this item. | | |
| | | | |
| | | T ime from a second | 26 |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | None | |
| | any entity (if not indicated in item #1 above). | | |
| 3 | Royalties or licenses | None | |
| , | noyunces of ficerises | NOTIC | |
| | | | |
| 4 | Consulting fees | None | |
| | | | |

| 5 | Payment or honoraria for | None | |
|----|------------------------------|-----------------------------|-------------------------|
| | lectures, presentations, | | |
| | speakers bureaus, | | |
| | manuscript writing or | | |
| | educational events | | |
| 6 | Payment for expert | None | |
| | testimony | | |
| | | | |
| 7 | Support for attending | None | |
| | meetings and/or travel | | |
| 8 | Patents planned, issued or | None | |
| | pending | | |
| | | | |
| 9 | Participation on a Data | Bayer, Provectus | |
| | Safety Monitoring Board or | | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role | Medical Advisory | |
| | in other board, society, | Committee (Cooper Rice- | |
| | committee or advocacy | Brading Foundation, | |
| | group, paid or unpaid | unpaid) | |
| | | Director of Australia and | |
| | | New Zealand Sarcoma | |
| | | Association (unpaid) | |
| 11 | Stock or stock options | None | |
| | | | |
| | | | |
| 12 | Receipt of equipment, | None | |
| | materials, drugs, medical | | |
| | writing, gifts or other | | |
| | services | | |
| 13 | Other financial or non- | None | |
| | financial interests | | |
| | | | |
| | Please summarize th | e above conflict of interes | t in the following box: |

Angela Hong received consultancy fee from Bayer and Provectus. She is a committee member for the Cooper Rice-Brading Foundation and a director of the Australia and New Zealand Sarcoma Association.

Please place an "X" next to the following statement to indicate your agreement: